Format

Send to

Choose Destination
Nat Rev Cancer. 2012 Jul 19;12(8):540-52. doi: 10.1038/nrc3319.

The rationale for targeting the LOX family in cancer.

Author information

1
Hypoxia & Metastasis Team, The Institute of Cancer Research, London SW3 6JB, UK.

Abstract

The therapeutic targeting of extracellular proteins is becoming hugely attractive in light of evidence implicating the tumour microenvironment as pivotal in all aspects of tumour initiation and progression. Members of the lysyl oxidase (LOX) family of proteins are secreted by tumours and are the subject of much effort to understand their roles in cancer. In this Review we discuss the roles of members of this family in the remodelling of the tumour microenvironment and their paradoxical roles in tumorigenesis and metastasis. We also discuss how targeting this family of proteins might lead to a new avenue of cancer therapeutics.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01323933.

PMID:
22810810
DOI:
10.1038/nrc3319
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center